Boehringer nears FDA nod for COPD combo; Zosano tees up $70M IPO;

@FierceBiotech: Amgen successfully hits another PhIII goal line with kidney dialysis drug. Story | Follow @FierceBiotech

@JohnCFierce: On again: Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Article | Follow @JohnCFierce

@DamianFierce: If Zosano Pharma pulls off its IPO this week, it'll be the 52nd biotech to go public this year, per . | Follow @DamianFierce

@EmilyMFierce: Over-hyped headline, but excellent points here: You Are Not Nearly Scared Enough About Ebola. More | Follow @EmilyMFierce

> The FDA accepted Boehringer Ingelheim's application for a fixed-dose combination of the COPD treatments tiotropium and olodaterol, a combo therapy poised to compete with inhalers from GlaxoSmithKline ($GSK) and Novartis ($NVS). The company isn't disclosing when it expects a final decision from the agency. More

> Zosano Pharma, a company developing needle-free drug delivery technology, is expected to price a $70 million IPO this week, which would make it the 52nd biotech to go public in 2014. News

> FDA investigators found dead frogs, moldy surfaces and falsified data at an Indian manufacturing plant. Story

Medical Device News

@FierceMedDev: Blood test for drug-resistant malaria strain shows promise. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: Abbott gets $20M from DoD to develop portable concussion test. Article | Follow @StacyALawrence

@VarunSaxena2: My photo was published in @indystar! George Will: Progressives as economic innocents. Story via IndyStar | Follow @VarunSaxena2

@EmilyWFierce: Medtronic sticks to its guns on Covidien and reports strongest quarterly U.S. sales growth in 5 years. More from Reuters | Follow @EmilyWFierce

> Leading U.S. hospital group target of external cyberattack. News

> Feds looking to fund clinical studies on cardiology, hip fracture and surgical mesh, among other topics. More

> Cheap, portable Dx device detects an array of medical and environmental conditions. Article

Pharma News

@FiercePharma: Top-read on FP Monday: Should deal-needy Pfizer target antibiotics specialist Cubist? Article | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: @NovoNordisk CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton

@EricPFierce: Indian drugmaker, Marck Biosciences, ravaged by FDA warning letter for records kept on 'scratch paper.' Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Reckitt Benckiser chief ahead of the consumer health curve, analysts say. Article | Follow @CarlyHFierce

> Merck seeking dismissal of Fosamax femur-fracture suits. Story

> Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion. Report

> Big investors urge drugmakers to stop badmouthing biosimilars. Article

Biotech Research News

> Bacteria injection shrinks tumors in animals. Report

> Diabetes culprit may be a single enzyme. Story

> Researchers unveil lung-on-a-chip device. Article

> Ebola protein discovery could aid drug development. More

> Organovo 3-D printed liver tissue moves closer to market. Item

Pharma Manufacturing News

> FDA warning letter says Marck plant plagued by faked records and dead frogs. Report

> Sweden's Recipharm moves on Italy with $160M deal for Corvette. More

> Big Pharma stands back as little guys work on plant-based drugs and manufacturing. Report

> Sun Pharma recalls nearly 500,000 bottles of antibiotics. Story

> Sanofi shipping new malaria treatment manufactured from 'semisynthetic artemisinin.' Article

Suggested Articles

A new, late-phase analysis of the cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year-and-a-half.

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.